Literature DB >> 15448661

Second cord blood transplantation (CBT) with reduced-intensity conditioning for graft failure after the first CBT for AML.

C Ohwada, C Nakaseko, S Ozawa, M Takeuchi, K Shono, M Koizumi, E Sakaida, R Cho, Y Saito, M Nishimura.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15448661     DOI: 10.1038/sj.bmt.1704696

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  5 in total

1.  Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation.

Authors:  Masahiko Sumi; Ikuo Shimizu; Keijiro Sato; Toshimitsu Ueki; Daigo Akahane; Mayumi Ueno; Naoaki Ichikawa; Shinji Nakao; Hikaru Kobayashi
Journal:  Int J Hematol       Date:  2010-11-05       Impact factor: 2.490

2.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

3.  Cord blood transplantation using minimum conditioning regimens for patients with hematologic malignancies complicated by severe infections.

Authors:  Takeshi Yamashita; Chiharu Sugimori; Ken Ishiyama; Hirohito Yamazaki; Hirokazu Okumura; Yukio Kondo; Akiyoshi Takami; Shinji Nakao
Journal:  Int J Hematol       Date:  2008-12-25       Impact factor: 2.490

4.  Switching of donor cells after urgent second cord blood transplantation for suspected graft failure.

Authors:  Naoko Satoh; Shoko Takenouchi; Shigeo Hashimoto; Masahiro Fujiwara; Tadashi Koike
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

Review 5.  Second hematopoietic stem cell transplantation in myeloid malignancies.

Authors:  Lisa M Arfons; Marcie Tomblyn; Vanderson Rocha; Hillard M Lazarus
Journal:  Curr Opin Hematol       Date:  2009-03       Impact factor: 3.284

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.